Tag: intraperitoneal chemotherapy

Recent advances have been demonstrated with the administration of intraperitoneal (IP) cisplatin and paclitaxel, where women with stage III ovarian disease conferred additional survival benefit as compared to conventional intravenous (IV) chemotherapy. However, due to concerns surrounding toxicity and difficulty administering IP therapy, less than half of the eligible...
Screening for breech presentation using universal late-pregnancy ultrasonography: A prospective cohort study and cost effectiveness analysis Fetal presentation has long been determined by way of clinical examination only, despite the relative ease with which breech presentation can be identified through ultrasound screening. As such, many women continue to present in...
1. In a prospective cohort study of over 800 patients with stage III ovarian cancer, less than 50% of all eligible patients received combined intraperitoneal and intravenous (IP/IV) chemotherapy during the study period. 2. The use of IP/IV chemotherapy was associated with an increased rate of 3-year overall survival compared...